AU2002210795A1 - Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils - Google Patents

Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils

Info

Publication number
AU2002210795A1
AU2002210795A1 AU2002210795A AU1079502A AU2002210795A1 AU 2002210795 A1 AU2002210795 A1 AU 2002210795A1 AU 2002210795 A AU2002210795 A AU 2002210795A AU 1079502 A AU1079502 A AU 1079502A AU 2002210795 A1 AU2002210795 A1 AU 2002210795A1
Authority
AU
Australia
Prior art keywords
thrombolytic
combination
inhibitory factor
conditions involving
pathophysiological conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002210795A
Other languages
English (en)
Inventor
Paul Butler
Suresh Babubhai Chahwala
Michael Chopp
Michael Krams
Michael Looby
Fion Macintyre
Andrew Brian Mcelroy
Aileen Dorothy Mcharg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002210795A1 publication Critical patent/AU2002210795A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002210795A 2000-10-17 2001-10-15 Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils Abandoned AU2002210795A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0025473.0A GB0025473D0 (en) 2000-10-17 2000-10-17 Pharmaceutical combinations
GB0025473.0 2000-10-17
GB0025473 2000-10-17
PCT/IB2001/001936 WO2002032446A2 (fr) 2000-10-17 2001-10-15 Combinaisons pharmaceutiques

Publications (1)

Publication Number Publication Date
AU2002210795A1 true AU2002210795A1 (en) 2002-04-29

Family

ID=9901490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002210795A Abandoned AU2002210795A1 (en) 2000-10-17 2001-10-15 Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils

Country Status (13)

Country Link
US (1) US20020098179A1 (fr)
AP (1) AP2001002295A0 (fr)
AR (1) AR034698A1 (fr)
AU (1) AU2002210795A1 (fr)
DO (1) DOP2001000266A (fr)
GB (1) GB0025473D0 (fr)
GT (1) GT200100207A (fr)
HN (1) HN2001000232A (fr)
PA (1) PA8530701A1 (fr)
PE (1) PE20020536A1 (fr)
TN (1) TNSN01142A1 (fr)
UY (1) UY26969A1 (fr)
WO (1) WO2002032446A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20030219431A1 (en) * 2002-05-24 2003-11-27 Empire Pharmaceuticals, Inc. Treatment of neuronal and neurological damage associated with spinal cord injury
CN1310949C (zh) * 2003-01-13 2007-04-18 重庆富进生物医药有限公司 具有抑制白细胞功能和凝血酶活性的双功能嵌合蛋白
CA2426115A1 (fr) * 2003-04-18 2004-10-18 Victor Gurewich Methodes, dispositifs et compositions pour la lyse des caillots sanguins occlusifs tout en protegeant les caillots qui obturent les blessures
CA2578224A1 (fr) * 2004-08-25 2006-03-09 Essentialis, Inc. Formulations pharmaceutiques d'activateurs de canaux potassiques atp, et utilisations correspondantes
WO2006094120A2 (fr) * 2005-03-02 2006-09-08 The Regents Of The University Of California Traitement d'une embolie cerebro-vasculaire
US20070167419A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
AU2006335153B2 (en) 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
CN101245110B (zh) * 2007-02-16 2010-09-15 鲁南制药集团股份有限公司 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物
JP2010532383A (ja) * 2007-07-02 2010-10-07 エッセンシャリス，インク． カリウムａｔｐチャネル開口薬の塩およびその使用
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
JP6005514B2 (ja) 2009-06-10 2016-10-12 ノノ インコーポレイテッド 神経疾患の治療のためのモデル系及び治療計画
US10064910B2 (en) * 2011-06-24 2018-09-04 Nono Inc. Combination therapy for ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2016073514A2 (fr) 2014-11-03 2016-05-12 Thrombolytic Science, Llc Méthodes et compositions pour thrombolyse sûre et efficace
US10336827B2 (en) 2015-10-29 2019-07-02 Wayne State University Compositions and methods to treat solid tumors
EP3411022B1 (fr) * 2016-02-01 2021-09-15 Emory University Particules pour distribution ciblée et utilisations dans la gestion de saignement ou de coagulation sanguine
WO2018232305A1 (fr) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Procédés et compositions pour la thrombolyse
CN116669757A (zh) * 2020-11-17 2023-08-29 泰伦基国际有限公司 一种提高bdnf水平的方法和药物
WO2022261282A1 (fr) * 2021-06-09 2022-12-15 Proniras Corporation Procédés de traitement ou de prévention d'états associés à un sevrage aux opiacés ou à une rechute aux opiacés

Also Published As

Publication number Publication date
PE20020536A1 (es) 2002-06-20
UY26969A1 (es) 2002-06-20
HN2001000232A (es) 2002-04-22
AP2001002295A0 (en) 2001-12-31
DOP2001000266A (es) 2002-05-31
TNSN01142A1 (fr) 2005-11-10
US20020098179A1 (en) 2002-07-25
WO2002032446A3 (fr) 2002-07-11
GB0025473D0 (en) 2000-11-29
AR034698A1 (es) 2004-03-17
WO2002032446A2 (fr) 2002-04-25
PA8530701A1 (es) 2003-06-30
GT200100207A (es) 2002-08-19

Similar Documents

Publication Publication Date Title
AU2002210795A1 (en) Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils
AU2002211340A1 (en) Systems and methods for preventing and/or reducing corrosion in various articles
IL173990A0 (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
TW479766U (en) Rack and pinion type swinging actuator
AU2221801A (en) Glass for use in freezer/refrigerator and glass article using said glass
AU2002225688A1 (en) Integrated graphics processing unit with antialiasing
AU2001272788A1 (en) Parallel z-buffer architecture and transparency
IL144490A0 (en) Transparent polymer articles of low thickness
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
HK1045890A1 (zh) 貿易系統和方法
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2001276959A1 (en) Methods, system, and article for displaying privilege state data
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
AU5073100A (en) Pyridine carboxamides and their use as plant protection agents
AU2002334983A1 (en) Inhibition of biological degradation in fischer-tropsch products
AU7475000A (en) Retroreflective articles having multilayer films and methods of manufacturing same
AP2001002329A0 (en) Thiazolidinedione derivative and its use as antibiotic
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
AU2001271483A1 (en) Method for imaging inclusions and/or alpha case in articles
AU2002340251A1 (en) Use of mx gtpases in the prognosis and treatment of cancer
AU2001237025A1 (en) Antimicrobial composition and articles
AU2002348534A1 (en) Materials and methods for preventing or reducing scar formation
AU2001253521A1 (en) Haplotypes of the cxcr4 gene
AU5220800A (en) Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments
AU2001231987A1 (en) Polyanionic polyglycosides in the treatment of autism